KVUE

In the past six months, Kenvue's stock has been impacted by several key events. In November 2025, Kenvue announced a deal to be fully acquired by Kimberly-Clark, expected to close in the second half of 2026, which is seen as providing shareholders with a defined monetization path and expected cost savings. Quarterly earnings reports showed stronger top- and bottom-line performance in Q4 2025, with net sales increasing 3.2% and diluted EPS at $0.17. Q1 2026 saw EPS of $0.25 and revenue of $3.91 billion, both exceeding analyst estimates. Q2 2026 marked the third consecutive quarter of net and organic sales growth, with net sales up 3.0% and adjusted diluted EPS at $0.31, though revenue slightly missed expectations. Kenvue has consistently declared quarterly cash dividends, increasing its dividend in July 2026. Tylenol-related litigation risk increased in July 2026 after a prior dismissal was vacated, with Kenvue unable to reasonably estimate potential liability. Due to the pending transaction with Kimberly-Clark, Kenvue has suspended providing forward-looking guidance, which could increase uncertainty.